13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002010850
Total reported value
$731.7M
$731.7M
26 檔
43.1%
At the close of Q3 2024, Decheng Capital LLC disclosed equity holdings valued at approximately $731.7M, spread across 26 reported holdings.
During Q3 2024, Decheng Capital LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including CGON, NUVB, PHAT) accounted for 43.1% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 48.96% | -3.34% | +0.37% | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 14.08% | +3.31% | +273.43% | |
| 3 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 5.35% | — | +47.06% | |
| 4 | RCUS | Arcus Biosciences Inc | Stock-Other | 3.15% | +0.40% | — | |
| 5 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 3.09% | -0.29% | EXIT | |
| 6 | ILMN | Illumina Inc | Stock-Healthcare | 2.93% | — | -12.87% | |
| 7 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 2.71% | +0.41% | +1.23% | |
| 8 | ✓ | Beyondspring Inc Shs | Stock-Other | 2.69% | -0.03% | — | |
| 9 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.32% | -0.75% | +47.50% | |
| 10 | ✓ | Merus N V | Stock-Other | 2.24% | — | +5.58% | |
| 11 | ✓ | Moonlake Immunotherapeutics | Stock-Other | 1.99% | — | — | |
| 12 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.91% | — | — | |
| 13 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.25% | — | +10.15% | |
| 14 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.18% | — | — | |
| 15 | AURA | Aura Biosciences Inc | Stock-Other | 1.09% | — | — | |
| 16 | WGS | Genedx Holdings CORP | Stock-Other | 1.04% | — | — | |
| 17 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.02% | — | +14.37% | |
| 18 | EQ | Equillium Inc | Stock-Other | 0.88% | +0.60% | — | |
| 19 | VERA | Vera Therapeutics Inc | Stock-Other | 0.73% | — | — | |
| 20 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 0.44% | — | — | |
| 21 | ACLXGBX | Arcellx Inc | Stock-Other | 0.42% | — | +1699.24% | |
| 22 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.28% | +0.06% | — | |
| 23 | ATRC | Atricure Inc | Stock-Other | 0.18% | — | — | |
| 24 | GRAL | Grail Inc | Stock-Healthcare | 0.03% | — | -46.58% | |
| 25 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.02% | -0.03% | — | |
| 26 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Decheng Capital LLC reported a total U.S. public equity portfolio value of $731.7M across 26 disclosed positions in Q3 2024.
During Q3 2024, Decheng Capital LLC's top holdings by market value included CGON (49.0%)、NUVB (14.1%)、PHAT (5.3%). The largest single position, CGON, represented 49.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q3 2024, Decheng Capital LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.